InsiderSignal.AI

InsiderSignal.ai

ABEO - Abeona Therapeutics Inc.

Insider Sale by Seshadri Vishwas (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Seshadri Vishwas, serving as CEO at Abeona Therapeutics Inc. (ABEO), sold 29,985 shares at $4.38 per share, for a total transaction value of $131,481.00. Following this transaction, Seshadri Vishwas now holds 1,430,423 shares of ABEO.

This sale represents a 2.00% decrease in Seshadri Vishwas's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, March 31, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 31, 2026, meaning the disclosure happened on the same day as the trade.

Abeona Therapeutics Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Seshadri Vishwas

CEO

Vishwas Seshadri, Ph.D., M.B.A., is the President, Chief Executive Officer, and Director of Abeona Therapeutics Inc. (ABEO), a gene and cell therapy company.[[1]](https://www.marketscreener.com/insider/VISHWAS-SESHADRI-A397XP/)[[2]](https://theorg.com/org/abeona-therapeutics/org-chart/vishwas-seshadri)[[4]](https://www.abeonatherapeutics.com/about) He joined Abeona in June 2021 as Head of Research & Clinical Development and was appointed to his current leadership roles in October 2021.[[2]](https://theorg.com/org/abeona-therapeutics/org-chart/vishwas-seshadri)[[4]](https://www.abeonatherapeutics.com/about) Dr. Seshadri has over 20 years of experience in life sciences, including senior roles at Bristol-Myers Squibb (formerly Celgene), where he led the launch of Breyanzi®, a CAR T cell therapy for lymphoma, and at Dr. Reddy's Laboratories as Head of Early-Stage Upstream Process Development for Biologics.[[1]](https://www.marketscreener.com/insider/VISHWAS-SESHADRI-A397XP/)[[2]](https://theorg.com/org/abeona-therapeutics/org-chart/vishwas-seshadri)[[3]](https://innovation.weill.cornell.edu/news-events/academic-scientist-biotech-executive-dr-vishwas-seshadri-inspires-abi-participants-his) Dr. Seshadri earned his Ph.D. in Microbiology, Immunology & Molecular Biology and completed a post-doctoral fellowship in epigenetics at the University of Arizona.[[1]](https://www.marketscreener.com/insider/VISHWAS-SESHADRI-A397XP/)[[2]](https://theorg.com/org/abeona-therapeutics/org-chart/vishwas-seshadri)[[3]](https://innovation.weill.cornell.edu/news-events/academic-scientist-biotech-executive-dr-vishwas-seshadri-inspires-abi-participants-his)[[4]](https://www.abeonatherapeutics.com/about) He holds an M.B.A. in Finance and Healthcare from The Wharton School of the University of Pennsylvania.[[1]](https://www.marketscreener.com/insider/VISHWAS-SESHADRI-A397XP/)[[2]](https://theorg.com/org/abeona-therapeutics/org-chart/vishwas-seshadri)[[3]](https://innovation.weill.cornell.edu/news-events/academic-scientist-biotech-executive-dr-vishwas-seshadri-inspires-abi-participants-his)[[4]](https://www.abeonatherapeutics.com/about) His career spans academia, process development, regulatory submissions, and commercialization of novel therapies, with early research at Stanford University Medical School and Howard Hughes Medical Institute.[[3]](https://innovation.weill.cornell.edu/news-events/academic-scientist-biotech-executive-dr-vishwas-seshadri-inspires-abi-participants-his)[[4]](https://www.abeonatherapeutics.com/about)

View full insider profile →

Trade Price

$4.38

Quantity

29,985

Total Value

$131,481.00

Shares Owned

1,430,423

Trade Date

Tuesday, March 31, 2026

5 days ago

SEC Filing Date

Tuesday, March 31, 2026

HEALTHCAREBIOTECHNOLOGY

About Abeona Therapeutics Inc.

Company Overview

No company information available
View news mentioning ABEO

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5260551

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime